# US 2024/0189373 A1 · Bacteriophage compositions for treating staphylococcus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189373 A1
- Document ID: US20240189373A1
- Status: Published application
- Kind: A1
- Application number: 18/593,476
- Filed: 2024-03-01
- Published: 2024-06-13
- Earliest claimed: 2020-02-18
- Assignees: Armata Pharmaceuticals, Inc.
- Applicants: Armata Pharmaceuticals, Inc.
- Inventors: Stacey Lynn KOLAR; Brian C. VARNUM
- Web page: https://patentgrep.com/patent/US20240189373A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2795/10132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Staphylococcus, and use of the same for treating Staphylococcus, e.g. Staphylococcus aureus, bacterial infections.

## Claims

### Claim at position 1

1-69. (canceled)

### Claim 70

A method for treating a bacterial infection comprising administering to a subject in need of treatment a bacteriophage composition comprising one or more bacteriophages selected from a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO:1, and a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO:2, wherein the composition comprises between 1×108 and 1×1011 PFU of each bacteriophage.

### Claim 71 (depends on 70)

The method of claim 70, wherein the composition is administered at a dosage of at least 1×109 PFU of total bacteriophages per milliliter.

### Claim 72 (depends on 70)

The method of claim 70, wherein the bacterial infection comprises a pulmonary infection, rhinosinusitis, urinary tract infection, intra-abdominal infection, skin infection, skin structure infection, bacteremia, septicemia, endocarditis, or an implant infection.

### Claim 73 (depends on 72)

The method of claim 72, wherein the implant infection comprises a cardiac implant infection, prosthetic joint infection, or prosthetic valve endocarditis.

### Claim 74 (depends on 70)

The method of claim 70, wherein the method further comprises administration of an antibiotic to the subject.

### Claim 75 (depends on 74)

The method of claim 74, wherein the antibiotic is from an antibiotic class selected from the group consisting of a fluoroquinolone, carbapenem, aminoglycoside, ansamycin, cephalosporin, penicillin, beta lactam, beta lactamase inhibitor, folate pathway inhibitor, fucidane, glycopeptide, glycylcycline, lincosamide, lipopeptide, macrolide, oxazolidinone, phenicol phosphonic acid, streptogramin, and tetracycline.

### Claim 76 (depends on 70)

The method of claim 70, wherein the bacterial infection is bacteremia.

### Claim 77 (depends on 70)

The method of claim 70, wherein the bacterial infection is resistant to an antibiotic.

### Claim 78 (depends on 70)

The method of claim 70, wherein the bacteriophage composition is administered intravenously, via intra-articular injection, via inhalation, or via nebulization.

### Claim 79 (depends on 70)

The method of claim 70, wherein the bacteriophage is administered at least every 6 hours, at least every 12 hours, or at least every 24 hours.

### Claim 80 (depends on 70)

The method of claim 70, wherein the bacteriophage is administered for at least 7 days.

### Claim 81 (depends on 70)

The method of any claim 70, wherein the subject is human.

### Claim 82 (depends on 70)

The method of claim 70, wherein the bacterial infection is caused by Staphylococcus aureus.

### Claim 83 (depends on 70)

The method of claim 70, wherein at least about 80% of bacteriophages in the bacteriophage composition retain lytic activity after exposure to human plasma for a time period between about 10 minutes and about 120 minutes.

### Claim 84 (depends on 70)

The method of claim 70, wherein the composition's target bacteria range is more effective than the sum of the efficacy of individual bacteriophages in the composition.

### Claim 85 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages comprise a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO:1.

### Claim 86 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages comprise a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO:2.

### Claim 87 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages comprise a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO:1, and a bacteriophage comprising a polynucleotide sequence with at least 95% identity to SEQ ID NO:2.

### Claim 88 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages are selected from a bacteriophage comprising the polynucleotide sequence of SEQ ID NO:1, and a bacteriophage comprising the polynucleotide sequence of SEQ ID NO:2.

### Claim 89 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages are resistant to blood complement inactivation.

### Claim 90 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages are resistant to complement C3 protein-mediated inactivation.

### Claim 91 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages belong to the genus Silviavirus.

### Claim 92 (depends on 70)

The method of claim 70, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.

### Claim 93 (depends on 70)

The method of claim 70, wherein the composition is a liquid, semi-liquid, solid, frozen, or lyophilized formulation.

### Claim 94 (depends on 70)

The method of claim 70, wherein the one or more bacteriophages of the composition target one or more of vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and methicillin-resistant (MRSA) Staphylococcus aureus.

### Claim 95 (depends on 70)

The method of claim 70, wherein the sequence of at least one bacteriophage is genetically modified.

### Claim 96 (depends on 70)

The method of claim 70, wherein the composition further comprises a storage medium for storage at a temperature at or below 8° C.

### Claim 97 (depends on 70)

The method of claim 70, wherein the composition is substantially free of a bacterial component, and wherein the bacterial component comprises bacterial host protein.

### Claim 98 (depends on 70)

The method of claim 70, wherein the composition is in a container containing from about 1 ml to about 5 ml of the composition, wherein the composition is an injectable solution.

### Claim 99 (depends on 70)

The method of claim 70, wherein at least one bacteriophage is obligately lytic.
